viewZelira Therapeutics Ltd

Zelda Therapeutics enters German medical cannabis market with partnership

The partnership provides access to the rapidly growing German market.

gear cog with the word collaboration written on it
The partnership precedes Zelda completing various clinical trials

Zelda Therapeutics Ltd (ASX:ZLD) has entered a distribution and manufacturing strategic partnership with German medicinal cannabis group HAPA Medical.

As per the deal, HAPA will have first rights to distribute and/or manufacture Zelda’s clinically validated formulations into the rapidly growing German market. 

READ: Zelda Therapeutics strengthens Scientific and Medical Advisory Board with two appointments

Zelda’s managing director Dr Richard Hopkins said: “This partnership re-enforces the global breadth of Zelda’s relationships and shows our focus on commercialising our clinically validated formulations.

“This is also important because Germany is expected to become the world’s single largest market for medicinal cannabis.”

With a population of 83 million people, Germany is estimated to have the potential to become the world’s largest single medical cannabis market.

HAPA attracted to Zelda’s science-driven approach

HAPA’s managing director Ricardo Pendón said: “We are delighted to be entering this partnership with Zelda which is positioned as one of the world’s leading science-driven medicinal cannabis companies.

“Growth in doctor and patient use is enabled by clinically validated data and having access to Zelda’s pipeline of products is an important success factor for us.”

Zelda remains focused on rapid commercialisation of its products subject to success in clinical trials.

READ: Zelda Therapeutics attracts new managing director, Dr Richard Hopkins

Germany is a very attractive market for Zelda with legislation passed in March 2017 allowing doctors to prescribe cannabis in certain circumstances.

Furthermore, recreational use and self-cultivation are prohibited in Germany.

Cannabis-related medicines potentially reimbursable

Under the German regulatory framework, the cost of cannabis-related medicines is potentially reimbursable for patients that register with their insurer.

The subsidised nature of the medicinal cannabis industry in Germany has catalysed growth in the number of registered patients that has far exceeded initial forecasts.

Quick facts: Zelira Therapeutics Ltd

Price: 0.054 AUD

Market: ASX
Market Cap: $52.18 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...



Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 21/2/20

2 min read